Famciclovir 250mg Tablets

Adult dose

1. Treatment of herpes zoster Adults: Administer 250 mg of famciclovir per dose orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of an initial episode of genital herpes Adults: Administer 250 mg of this drug per dose orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of an acute recurrence of genital herpes Adults: Administer 125 mg of this drug per dose orally 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this drug per dose orally 2 times daily. Temporarily discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the creatinine clearance of this drug is reduced in patients with renal impairment, dose adjustment should be undertaken with care. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and an initial episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 250 mg per dose once daily 2) Treatment of an acute recurrence of genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg per dose once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg per dose 2 times daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, administration every 48 hours is preferable, taking the interval between dialysis sessions into account. Since 4 hours of hemodialysis reduces the plasma concentration of this drug by approximately 75%, administer this drug immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is required for patients with chronic compensated liver disease. There is insufficient treatment experience in patients with evident chronic decompensated liver disease; therefore, a clear recommended dose has not been established

This medication should not be used by individuals who are allergic to this medication or its ingredients, especially to penciclovir. Additionally, since this medication contains lactose, patients with a genetic inability to digest lactose should not take it. Patients with impaired kidney function should use this medication with caution, and dose adjustments may be needed. Headache, dizziness, nausea, vomiting, abdominal pain, and diarrhea may occur while taking this medication, and some patients may also experience skin rashes or itching. Patients with weak liver function should also be cautious when using this medication, and there is not enough research on patients with severe liver impairment, so caution is necessary. This medication does not completely cure genital herpes, so it is important to avoid sexual contact and maintain safe sexual practices when symptoms are present. If symptoms such as dizziness, drowsiness, or confusion occur while taking this medication, driving or operating machinery should be avoided. This medication can interact with other drugs, so if there are any other medications being taken, it is essential to inform healthcare providers. Women who are pregnant or may become pregnant should carefully weigh the benefits and risks of using this medication, and breastfeeding women should also take precaution. Children under 18 years of age are not recommended to use this medication as its safety and effectiveness have not been established. Elderly patients usually do not need dose adjustments, but if kidney function is impaired, dosage should be adjusted. In case of overdose, immediate medical attention should be sought, and blood dialysis may be helpful. This medication should be stored away from direct sunlight and in a dry place below 30 degrees Celsius, and it is safest to keep it out of reach of children. Furthermore, transferring it to another container is not advisable as it may affect quality.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication should be stored in a tightly closed container to avoid exposure to air or moisture, preferably in a cool, dry place at temperatures below 30 degrees Celsius.

Appearance

White, round film-coated tablets

Package unit

For domestic use: 21 tablets (7 tablets/PTP x 3)